An antiarrhythmic effect of adenosine during myocardial ischaemia and reperfusion

European Journal of Pharmacology
C L Wainwright, J R Parratt


Adenosine (10 micrograms kg-1 min-1, infused into the lumen of the left ventricle) and dipyridamole (0.25 mg kg-1 intravenously, a dose that potentiated markedly the fall in arterial pressure in response to bolus doses of adenosine) each reduced the number of extrasystoles which occurred during the first 30 minutes following coronary artery occlusion in anaesthetised greyhound dogs (from 786 +/- 115 in control dogs to 156 +/- 44 in those treated with adenosine and to 388 +/- 167 with dipyridamole). Intracoronary adenosine (1 microgram kg-1 min-1, infused into the ischaemic area) however appeared to increase the number of extrasystoles to 1230 +/- 214. Left ventricular infusion of adenosine reduced the incidence of ventricular fibrillation (from 88 to 43%) when the ischaemic myocardium was perfused at the end of a 40 min occlusion period. In the dose used in this study (10 micrograms kg-1 min-1) adenosine caused a sustained fall in blood pressure but did not alter blood gases. In control dogs the levels of purine derivatives in blood draining the myocardium rendered ischaemic by coronary artery occlusion (local coronary venous samples) increased gradually during the ischaemic period (from 9 +/- 3 microM pre-occlusion to 25 +/- 7...Continue Reading


Nov 25, 1977·Pflügers Archiv : European journal of physiology·J SchraderE Gerlach
Jun 1, 1975·Journal of Molecular and Cellular Cardiology·J SchraderR M Berne
Jun 1, 1986·The American Journal of Cardiology·E MarchantP Casanegra
Jun 1, 1985·British Journal of Pharmacology·G Ciabattoni, A Wennmalm
Dec 1, 1980·Circulation Research·R M Berne
Aug 1, 1984·Pflügers Archiv : European journal of physiology·M T KnabbR M Berne
Mar 1, 1984·Naunyn-Schmiedeberg's Archives of Pharmacology·R SeitelbergerG Raberger
Apr 20, 1984·European Journal of Pharmacology·O Fagbemi, J R Parratt
Mar 1, 1980·Naunyn-Schmiedeberg's Archives of Pharmacology·A J SzentmiklósiL Szekeres


Jan 1, 1989·Neurochemistry International·M Williams
Mar 5, 2005·The Journal of Thoracic and Cardiovascular Surgery·Joel S CorveraJakob Vinten-Johansen
Dec 1, 1992·British Journal of Pharmacology·R Z GerencerA S Clanachan
Jun 1, 1993·British Journal of Pharmacology·C L WainwrightH Van Belle
Aug 20, 2004·American Journal of Physiology. Heart and Circulatory Physiology·Sarah J Canyon, Geoffrey P Dobson
Nov 1, 1995·Circulation Research·R Pabla, M J Curtis
Aug 31, 1999·Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences·C H Fu, P K McGuire
Apr 1, 1997·Journal of Cardiovascular Pharmacology·W Sun, C L Wainwright

Related Concepts

Cardiac Depressants
Blood Gas Analysis
Coronary Circulation
Coronary Heart Disease
Canis familiaris
Adenosine Deaminase Inhibitors

Related Feeds

Antiarrhythmic Agents: Mechanisms of Action

Understanding the mechanism of action of antiarrhythmic agents is essential in developing new medications as treatment of cardiac arrhythmias is currently limited by the reduced availability of safe and effective drugs. Discover the latest research on Antiarrhythmic Agents: Mechanism of Action here.

Anti-Arrhythmic Drug Therapies

Anti-arrhythmic drugs are used to prevent abnormal heart rhythms. These medications are used in conditions including, ventricular tachycardia, ventricular fibrillation and atrial fibrillation. Discover the latest research on anti-arrhythmic drug therapies here.


Arrhythmias are abnormalities in heart rhythms, which can be either too fast or too slow. They can result from abnormalities of the initiation of an impulse or impulse conduction or a combination of both. Here is the latest research on arrhythmias.